Phosphodiesterase 4 Inhibitors
"Phosphodiesterase 4 Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that specifically inhibit PHOSPHODIESTERASE 4.
| Descriptor ID |
D058988
|
| MeSH Number(s) |
D27.505.519.389.735.374
|
| Concept/Terms |
Phosphodiesterase 4 Inhibitors- Phosphodiesterase 4 Inhibitors
- Inhibitors, Phosphodiesterase 4
- PDE4 Inhibitors
- Inhibitors, PDE4
- Phosphodiesterase Type 4 Inhibitors
- PDE-4 Inhibitors
- Inhibitors, PDE-4
- PDE 4 Inhibitors
|
Below are MeSH descriptors whose meaning is more general than "Phosphodiesterase 4 Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Phosphodiesterase 4 Inhibitors".
This graph shows the total number of publications written about "Phosphodiesterase 4 Inhibitors" by people in this website by year, and whether "Phosphodiesterase 4 Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Phosphodiesterase 4 Inhibitors" by people in Profiles.
-
Granuloma Annulare: An Updated Review of Epidemiology, Pathogenesis, and Treatment Options. Am J Clin Dermatol. 2022 Jan; 23(1):37-50.
-
A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD. Respir Res. 2020 Feb 10; 21(1):47.
-
Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer. Clin Cancer Res. 2018 04 15; 24(8):1987-2001.
-
Phosphodiesterase 4 inhibitors. J Am Acad Dermatol. 2018 03; 78(3 Suppl 1):S43-S52.
-
Adherence to a COPD treatment guideline among patients in Hong Kong. Int J Chron Obstruct Pulmon Dis. 2017; 12:3371-3379.
-
Effect of roflumilast in patients with severe COPD and a history of hospitalisation. Eur Respir J. 2017 07; 50(1).
-
Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting ?2-agonist fixed-dose combination: RE(2)SPOND rationale and study design. Int J Chron Obstruct Pulmon Dis. 2016; 11:1921-8.
-
PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2016 08; 16 Suppl:S67-73.
-
Phosphodiesterase 4 Inhibitors Attenuate the Asthma Phenotype Produced by ?2-Adrenoceptor Agonists in Phenylethanolamine N-Methyltransferase-Knockout Mice. Am J Respir Cell Mol Biol. 2016 08; 55(2):234-42.
-
The Analgesic Effect of Rolipram, a Phosphodiesterase 4 Inhibitor, on Chemotherapy-Induced Neuropathic Pain in Rats. Anesth Analg. 2015 Sep; 121(3):822-828.